Merck & Co Inc

Merck & Co., Inc. (known as MSD outside the United States and Canada) is a global research-intensive biopharmaceutical company that discovers, develops, manufactures, and markets medicines, vaccines, and animal health products. Its pharmaceutical portfolio is anchored by KEYTRUDA (pembrolizumab), a blockbuster PD-1 immunotherapy used across numerous cancer indications, now complemented by the subcutaneous formulation KEYTRUDA QLEX. The company's oncology pipeline spans antibody-drug conjugates (sacituzumab tirumotecan), KRAS inhibitors (calderasib), and personalized cancer vaccines (with Moderna). Beyond oncology, Merck markets WINREVAIR for pulmonary arterial hypertension, GARDASIL 9 for HPV prevention, BRIDION for neuromuscular blockade reversal, and recently launched LIPFENDRA, the first oral daily PCSK9 inhibitor for cholesterol management. The company is advancing tulisokibart in immunology, islatravir-based regimens in HIV, and CAPVAXIVE in pneumococcal disease. Its Animal Health segment sells livestock and companion animal products globally, including the BRAVECTO parasiticide line. Merck generates revenue across the United States, Europe, Asia Pacific, Japan, China, Latin America, and other markets worldwide. Updated Oct 7, 2026